GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Assertio Holdings Inc (NAS:ASRT) » Definitions » Net Cash per Share

ASRT (Assertio Holdings) Net Cash per Share : $-0.60 (As of Sep. 2024)


View and export this data going back to 1997. Start your Free Trial

What is Assertio Holdings Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Assertio Holdings's Net Cash per Share for the quarter that ended in Sep. 2024 was $-0.60.

The historical rank and industry rank for Assertio Holdings's Net Cash per Share or its related term are showing as below:

During the past 13 years, the highest Price-to-Net-Cash Ratio of Assertio Holdings was 4.49. The lowest was 4.49. And the median was 4.49.

ASRT's Price-to-Net-Cash is not ranked *
in the Drug Manufacturers industry.
Industry Median: 8.325
* Ranked among companies with meaningful Price-to-Net-Cash only.

Assertio Holdings Net Cash per Share Historical Data

The historical data trend for Assertio Holdings's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Assertio Holdings Net Cash per Share Chart

Assertio Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -21.12 -7.99 -4.20 -2.55 -0.79

Assertio Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.17 -0.79 -0.70 -0.62 -0.60

Competitive Comparison of Assertio Holdings's Net Cash per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Assertio Holdings's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Assertio Holdings's Price-to-Net-Cash Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Assertio Holdings's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Assertio Holdings's Price-to-Net-Cash falls into.



Assertio Holdings Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Assertio Holdings's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

Net Cash per Share (A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(73.441-148.416-0)/94.6685
=-0.79

Assertio Holdings's Net Cash per Share for the quarter that ended in Sep. 2024 is calculated as

Net Cash per Share (Q: Sep. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(88.579-145.481-0)/95.3608
=-0.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Assertio Holdings  (NAS:ASRT) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Assertio Holdings Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Assertio Holdings's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Assertio Holdings Business Description

Traded in Other Exchanges
N/A
Address
100 South Saunders Road, Suite 300, Lake Forest, IL, USA, 60045
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
Executives
Heather L Mason director 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Jeff L Vacirca director 4747 EXECUTIVE DRIVE, SUITE 510, SAN DIEGO CA 92121
James L Tyree director 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064-6400
Daniel A. Peisert director, officer: President & CEO C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Paul Schwichtenberg officer: SVP and CFO 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Ajay Patel officer: SVP and CAO 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Sam Schlessinger officer: SVP, General Counsel 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FORREST IL 60045
William Mckee director
Crg Partners Iii - Parallel Fund (a) L.p. 10 percent owner C/O CAPITAL ROYALTY L.P., 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Todd N Smith director, officer: Director, Pres & CEO 1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062
Mark Strobeck officer: EVP & Chief Operating Officer 460 EAST SWEDESFORD ROAD, SUITE 1050, WAYNE PA 19087
Crg Partners Iii L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Cr Group L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Andrea Heslin Smiley director 600 LEE ROAD, SUITE 100, WAYNE PA 19087
Megan C. Timmins officer: SVP, Gen Csl & Sec 600 LEE ROAD, SUITE 100, WAYNE PA 19087